Navigation Links
Sequenom Announces Participation at the 23rd Annual Piper Jaffray Healthcare Conference
Date:11/22/2011

SAN DIEGO, Nov. 22, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 23rd Annual Piper Jaffray Healthcare Conference at the Palace Hotel in New York City November 29-30, 2011.

Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development and Paul V. Maier, CFO, will present on Tuesday, November 29, 2011 beginning at 8:30 a.m. ET, to provide an overview of and update on the Company.  The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com.  An audio replay will be available for 30 days following the initial presentation web cast.  

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)


'/>"/>
SOURCE Sequenom, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sequenom to Host Analyst Day on Monday, November 14, 2011
2. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
3. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
4. Sequenom Center for Molecular Medicine Announces Launch of MaterniT21™ Noninvasive Prenatal Test for Down Syndrome
5. Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System
6. Sequenom, Inc. Announces Date of Second Quarter 2011 Financial Results and Conference Call
7. Sequenom Enters Into New $30.0 Million Credit Facility
8. Sequenom Announces Participation at Jefferies 2011 Global Healthcare Conference
9. Sequenom Announces Publication Acceptance of Manuscript From Age-related Macular Degeneration Validation Study
10. Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study
11. Sequenom Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):